Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

The “magic” weight loss drug that’s everywhere—TikTok ... They’ve expanded from treating erectile dysfunction and hair loss to offering weight loss solutions, including semaglutide. Ro’s strength is ...

Heart disease is a type of cardiovascular disease that affects the heart’s structure and function. Several different heart ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer ... In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news. Market Domination ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...